English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

s of the 4th Congress of ECCO the European Crohn’s and Colitis Organisation S65 P136 Efficacy and safety of adalimumab in children with active Crohn’s disease: a prospective, open-label, single-centre trial F. Civitelli *, F. Viola, S. Oliva, F. Nuti, E. Romeo, G. Di Nardo, V. Pannone, O. Borrelli, S. Cucchiara. Sapienza University, Rome, Italy Adalimumab (ADA) (HUMIRA, Abbott ®), a fully human IGG1 anti-TNFa monoclonal antibody, is effective in inducing and maintaining remission in adult patients (pts) with active Chron’s Disease (CD), regardless of previous experience with anti-TNFa therapy. There are only few data on its use in pediatric pts with CD. Aim: To prospectively evaluate efficacy and safety of ADA in pediatric pts with moderate to severe CD. Patients and Methods: 23 CD pts, median age 16.1 years (range 9 20), naive to (9 pts) or who had failed prior Infliximab (IFX) therapy (14 pts) received ADA. The induction schedule at week (wk) 0 and 2 was 160mg/80mg in 13 pts, 80mg/40mg in 8 pts, followed respectively by 80mg or 40mg every other week (eow) during the 44 wks maintenance phase. Two pts received an induction dose of 120mg/80mg, followed by 80mg eow. Primary outcomes were: clinical remission (PCDAI score 10), clinical response (decrease in PCDAI score of 50% versus baseline), safety of the therapeutic course at wk 2, 4, 12, 24 and 48. ITT analysis including all pts who received at least 1 dose of ADA was performed. Results: mean disease duration at the beginning of ADA course was 52.2±42.5 months (mts). Fourteen pts had previously received IFX therapy (9.2±8.2 doses), discontinued due to loss of efficacy (11 pts) or intolerance (3 pts). Mean time between the last IFX dose and the beginning of ADA was 19.2±15.5 mts. At baseline 13 pts were receiving concomitant immumnomodulators (IM); only 2 pts at wk 48. Mean oral corticosteroids dose (mg/kg/day) was 0.9±0.2mg at the beginning of the trial, 0.07±0.1 at wk 48 (p < 0.001). The mean PCDAI, ESR, CRP values at each study point are shown in the table. Rates of remission at wk 2, 4, 12, 24 and 48 were: 36.3%; 60.8%; 30.5%; 50% and 65.2%. Rates of response were respectively: 54.5%; 34.8%; 39.1%; 40.9%; 30.4%. During the maintenance phase 5/8 pts receiving 40mg eow had to increase ADA dose to 80mg eow in order to maintain clinical remission; 6/13 pts receiving 80mg eow were able to shift to 40mg eow without CD exacerbation. Only 2 pts presented a serious adverse event requiring temporary cessation of ADA: 1 within wk 24 (abdominal abscess), 1 through wk 48 (severe cutaneous infection).

P136 - Efficacy and safety of adalimumab in children with active Crohn's disease: a prospective, open-label, single-centre trial